Cite

HARVARD Citation

    Fang, Q. et al. (2022). The impact of venetoclax based regimens in the preemptive of measurable residual disease in acute myeloid leukemia. Blood science. 4 (1), pp. 44-46. [Online]. 
  
Back to record